Sialorphin TFA 

Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease^{[1][2][3][4][5]}.

Sialorphin (10 μM; 20 min) inhibits the degradation of Met-enkephalin (ME) in rat spinal cord slices with an inhibition rate of 70%-96%, and simultaneously inhibits the hydrolysis of ³H-SP in spinal cord tissues (membranes or slices) with an inhibition rate of 55%. Its IC₅₀ for inhibiting ³H-SP degradation is 3.9×10^-7 M^[1].
Sialorphin (400 nM-4000 nM; 10-20 min) exerts a concentration-dependent inhibitory effect on endopeptidase-mediated hydrolysis of ³H-SP in rat renal cell membranes, with an IC₅₀ of 1 μM. This inhibition is competitive and comparable in efficacy to that of phosphoramidon^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sialorphin TFA (0.3-10 mg/kg; i.p.; twice daily; 3 days) at doses of 0.3, 1, and 3 mg/kg significantly attenuates acute TNBS-induced colitis in Mus musculus, as measured by reduced macroscopic damage, ulceration, colonic wall thickening, and MPO activity^[2].
Sialorphin TFA (1 mg/kg; i.p.; twice daily; 7 days) significantly attenuates chronic, relapsing TNBS-induced colitis in mice, as measured by reduced clinical, biochemical, histological, and cytokine markers of inflammation^[2].
Sialorphin TFA (1 mg/kg; i.p.; twice daily; 7 days) does not exhibit anti-inflammatory activity in DSS-induced colitis in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

650.69 (free base)

C₂₆H₄₂N₁₂O₈·xC₂HF₃O₂

Solid

Gln-His-Asn-Pro-Arg

QHNPR

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Rougeot C, et al. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. Proc Natl Acad Sci U S A. 2003;100(14):8549-8554.  [Content Brief]

  [2]. Salaga M, et al. Systemic Administration of Sialorphin Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors. J Crohns Colitis. 2017;11(8):988-998.  [Content Brief]

  [3]. Mizerska-Kowalska M, et al. Neutral endopeptidase (NEP) inhibitors–thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro[J]. Chemico-Biological Interactions, 2019, 307: 105-115.

  [4]. Kamysz E, et al. Antitumor activity of opiorphin, sialorphin and their conjugates with a peptide klaklakklaklak. J Pept Sci. 2016;22(11-12):723-730.  [Content Brief]

  [5]. Kamysz E, et al. Sialorphin and its analog as ligands for copper (II) ions[J]. Polyhedron, 2013, 55: 216-224.